Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target
Akhilesh Swaminathan, Andrew S. Day, Miles Sparrow, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1176-1199
Open Access | Times Cited: 10

Showing 10 citing articles:

Editorial: Leucine‐Rich Alpha‐2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease
Anna Mitchell, Akhilesh Swaminathan
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications
Christy Riggott, Alexander C. Ford, David J. Gracie
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1200-1214
Closed Access | Times Cited: 13
Review article: Evidence‐based dietary management of inflammatory bowel disease
Peter R. Gibson, Chu K Yao, Emma P. Halmos
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1215-1233
Open Access | Times Cited: 9
Review article: Prevention of inflammatory bowel disease—The path forward
Sérgio Bronze, Manasi Agrawal, Jean‐Frédéric Colombel, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1166-1175
Closed Access | Times Cited: 9
Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
Nurulamin M Noor, Alice Bourke, Sreedhar Subramanian
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1244-1260
Open Access | Times Cited: 9
Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
Thanaboon Chaemsupaphan, Rupert W. Leong, Niels Vande Casteele, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1234-1243
Open Access | Times Cited: 8
Treatment sequencing in inflammatory bowel disease : towards clinical precision medicine
Léa Sequier, Bénédicte Caron, Sailish Honap, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101994-101994
Closed Access
Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow‐Up
Christy Riggott, Keeley M. Fairbrass, David J. Gracie, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access
Letter: Extending the Measurement of Inflammatory Bowel Disease Severity to Include Patient Important Outcomes
Angela Forbes
Alimentary Pharmacology & Therapeutics (2024)
Closed Access | Times Cited: 1
Inflammatory bowel disease in 2024 and beyond
Richard B. Gearry, Cynthia H. Seow, Sreedhar Subramanian
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1164-1165
Open Access
Letter: Extending the Measurement of Inflammatory Bowel Disease Severity to Include Patient Important Outcomes—Authors' Reply
Akhilesh Swaminathan, Miles Sparrow, Richard B. Gearry
Alimentary Pharmacology & Therapeutics (2024)
Closed Access
Page 1

Scroll to top